Vir Biotechnology, Inc. SEC Filings

SVF Endurance (Cayman) Limited has filed a notice to sell 1,251,303 shares of VIR common stock through broker BTIG, LLC, with an approximate sale date of 01/14/2026 on NASDAQ. The filing lists an aggregate market value of $8533886.46 for these shares and notes that 139,125,032 shares of the issuer’s common stock are outstanding.

The seller’s shares were acquired on 10/16/2019 upon automatic conversion of convertible preferred stock that was fully paid for in multiple cash transactions completed by 01/31/2019. Over the past three months, the same holder has sold multiple blocks of common stock, including 220,535 shares on 10/20/2025 and 297,495 shares on 12/04/2025, with disclosed gross proceeds for each transaction.

Vir Biotechnology, Inc. reported that it has issued a press release providing a preliminary estimate of its cash, cash equivalents and investments balance as of December 31, 2025. This figure is unaudited and may change, and the company plans to report its full fourth quarter and full-year 2025 financial results in late February 2026.

The company also plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:45 p.m. PT. The related slide deck is being made available as an exhibit and on the company’s investor website, which will also host a live webcast and a 30-day archive of the presentation.

Vir Biotechnology director Vicki L. Sato sold 22,000 shares of common stock on January 2, 2026 at a weighted average price of $5.9265 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025.

Following this transaction, Sato beneficially owned 1,166,391 shares of Vir Biotechnology common stock, held in direct ownership.

Vir Biotechnology, Inc. entered a license agreement with Norgine Pharma UK Limited for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial EUR 55 million reimbursement of development costs and is eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales, while Norgine will contribute about 25% of go-forward external costs for Vir’s ECLIPSE registrational program.

Vir retained rights to the combination in the United States and most other markets outside the Greater China Territory. The company also highlighted Phase 2 SOLSTICE data in chronic hepatitis delta, where 66% (21/32) of participants on the monthly combination achieved sustained HDV RNA target not detected at Week 48, about 90% (29/32) reached hepatitis B surface antigen levels below 10 IU/mL, and 56% (18/32) achieved ALT normalization by Week 48, with the regimen reported as well-tolerated and no grade 3 or higher treatment-related adverse events or treatment-related discontinuations.

Vir Biotechnology, Inc. (VIR) disclosed that major shareholder and director-affiliated entity SVF Endurance (Cayman) Limited reported two open-market sales of Vir common stock. On 11/24/2025, it sold 227,803 shares at a weighted average price of $6.1491, and on 11/25/2025 it sold 235,971 shares at a weighted average price of $6.38. The sales were made under a Rule 10b5-1 trading plan entered into on September 3, 2025. After these transactions, the reporting person indirectly beneficially owned 14,110,209 Vir common shares, held of record by SVF Endurance (Cayman) Limited.

Vir Biotechnology, Inc. reported an insider stock transaction by its EVP & Chief Financial Officer. On 11/17/2025, the officer sold 6,799 shares of Vir common stock at a price of $5.557 per share. The company states this was an automatic sale to cover tax withholding and remittance obligations tied to the vesting of restricted stock units, meaning it was done for tax purposes rather than discretionary selling. After this transaction, the officer beneficially owns 110,701 shares of Vir common stock, which includes 2,500 shares acquired on May 30, 2025 through an employee stock purchase program.

Vir Biotechnology (VIR) reported an insider transaction by its EVP, General Counsel and Corporate Secretary. On 11/05/2025, the officer sold 2,385 shares of common stock at $5.16 per share, as indicated by transaction code S. Following the sale, the officer beneficially owns 78,210 shares, held directly.

The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 5, 2024.

Vir Biotechnology (VIR) reported Q3 2025 results with total revenue of $0.24 million and a net loss of $163.1 million (loss per share $1.17). Year-to-date, the company recorded a net loss of $395.1 million and used $365.9 million in operating cash.

Liquidity remained strong with $810.7 million in cash, cash equivalents and investments as of September 30, 2025, which management states is sufficient for at least twelve months. Q3 operating expenses totaled $173.7 million, driven by R&D of $151.5 million and SG&A of $22.2 million. The quarter included a $75.0 million milestone payment related to the Sanofi PRO-XTEN license; earlier in 2025, Vir paid $30.0 million under the restated Alnylam agreement and achieved a $17.5 million clinical milestone tied to tobevibart.

Clinical programs advanced: the ECLIPSE registrational program for chronic hepatitis delta has all trials underway, with ECLIPSE 1 enrollment completed ahead of plan and topline readouts for ECLIPSE 1–3 expected in Q1 2027. Oncology TCEs (VIR-5500, VIR-5818, VIR-5525) are in phase 1, with the first patient for VIR-5525 dosed in July 2025. Shares outstanding were 139,125,032 as of October 29, 2025.

Vir Biotechnology, Inc. furnished its quarterly results via an 8-K on November 5, 2025. The filing states that a press release announcing financial results for the quarter ended September 30, 2025 is attached as Exhibit 99.1 and incorporated by reference.

The company notes the information under Item 2.02 is being furnished and not deemed filed under the Exchange Act, limiting associated Section 18 liabilities. The common stock trades on the Nasdaq Global Select Market under the symbol VIR.